Skip to main
LGND

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals is a profitable company with a diverse portfolio of biopharmaceutical assets and a commitment to sustainability. Their projected revenues from royalties, material sales, and collaborative agreements, coupled with a strong management team and unique investment approaches, make them a stable long-term investment option. With a recent increase in their stock price estimate to $340 per share, Ligand shows promising potential for continued growth through partnerships and acquisitions.

Bears say

Ligand Pharmaceuticals is facing several significant risks that can negatively impact the company's operations and financial performance. These risks include a heavy reliance on a limited number of revenue sources, potential slowdown or decline in sales of key commercial assets, and the company's dependency on its Captisol material. Additionally, Ligand's business model is highly reliant on partnerships and licensing agreements, which can be unpredictable and subject to delays or failures. The company also faces risks related to its drug development pipeline, which may experience setbacks or failures, impacting its potential for future revenue growth. Despite management's focus on sustainability, environmental and operational risks could also impact the company's financial performance. Overall, these risks indicate a negative outlook for Ligand Pharmaceuticals' stock.

Ligand Pharmaceuticals (LGND) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Ligand Pharmaceuticals (LGND) has a Strong Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $335.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $335.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.